Clinical Trials Logo

Filter by:
NCT ID: NCT06347809 Enrolling by invitation - Clinical trials for Prostate Adenocarcinoma

DNA Methylation in Adenocarcinoma of the Prostate: Analysis of Validated Biomarkers in Urine

Start date: November 7, 2018
Phase:
Study type: Observational

This study explores the potential use of DNA markers in the detection of prostate cancer and patient perceptions of this screening approach and other current or future prostate cancer screening and diagnostic tests.

NCT ID: NCT06345638 Enrolling by invitation - Sickle Cell Disease Clinical Trials

Sex Hormones and Inflammatory Biomarkers in Patients With Sickle Cell Disease

Start date: March 1, 2024
Phase:
Study type: Observational

This study aims to characterize sex differences in the pathophysiology of vaso-occlusive crises (VOC) occurring among individuals with sickle cell disease (SCD). - The study will compare CRP and other biomarkers between females with SCD in the follicular phase of the menstrual cycle and males with SCD. - The study will explore potential sex differences in biomarker changes between females and males with SCD during and following resolution of VOC. - The study will compare neutrophil and platelet adhesion to the endothelium and real time fibrin deposition in the blood.

NCT ID: NCT06344026 Enrolling by invitation - Parkinson Disease Clinical Trials

Phase 1/2a Study of ANPD001 in Parkinson Disease

ASPIRO
Start date: January 23, 2024
Phase: Phase 1
Study type: Interventional

This clinical trial is designed to test the safety and tolerability of injecting ANPD001 cells that will mature into dopamine-producing cells into the brain of participants with Parkinson Disease. All participants will have ANPD001 cells manufactured from their own previously collected cells.

NCT ID: NCT06343636 Enrolling by invitation - Healthy Clinical Trials

A Phase 1 Study of VG-3927 in Healthy Adults

Start date: September 27, 2023
Phase: Phase 1
Study type: Interventional

A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VG-3927 in Healthy Adults

NCT ID: NCT06340919 Enrolling by invitation - Hearing Loss Clinical Trials

Hearing Aid Algorithms for Sudden Sounds

Start date: February 21, 2024
Phase: N/A
Study type: Interventional

This study explores the impact of hearing aid settings for managing sudden sounds on speech comprehension and recall in individuals with hearing loss. Participants will undergo a comprehensive audiological evaluation, case history, and cognitive assessments. Subsequently, they will participate in listening experiments designed to measure sentence recognition, storage, and retrieval under various sudden sound reduction conditions recorded through a hearing aid. The experiment will be complemented by subjective preference ratings to identify participant comfort and listening clarity associated with different sudden sound reduction settings.

NCT ID: NCT06340321 Enrolling by invitation - Obesity Clinical Trials

Impact of Metabolic Flexibility on Changes in Metabolic Health

METPROS
Start date: June 2024
Phase:
Study type: Observational

Metabolic flexibility is the capacity to adapt fuel oxidation to fuel availability so that ATP synthesis can match its cellular demands. Thus, for example, increases in glucose availability after a meal would increase glucose oxidation, while increases in lipid availability during fasting would increase lipid oxidation. Enhanced metabolic flexibility has been proposed to protect humans from metabolic diseases. Nevertheless, most studies examining associations between metabolic flexibility and metabolic health outcomes have used cross-sectional designs. Whether impaired metabolic flexibility causes or results from metabolic health impairment is thus unclear. In this study, the investigators will use the data from a study conducted approximately 16 years ago in healthy participants without obesity. Using the data already collected in that study, the metabolic flexibility of each participant will be calculated. To test the association between metabolic flexibility and the change in metabolic health, the investigators will call back all the participants for a single follow-up visit to reassess several metabolic health outcomes. Thus, the main aim of the study is to test the association between metabolic flexibility and the change in metabolic health outcomes after 16 years in humans.

NCT ID: NCT06335056 Enrolling by invitation - Waitlist Control Clinical Trials

Dissemination of an Adolescent Obesity Prevention Intervention to Louisiana Schools

ProudMe
Start date: February 19, 2024
Phase: N/A
Study type: Interventional

This project aims to test the effectiveness and implementation of an adolescent obesity prevention intervention called ProudMe. The study recruits 480 adolescents from 12 middle schools (cluster-randomized to 6 ProudMe schools vs 6 wait-list control schools) and expect to observe improvements of obesity-prevention behaviors and weight status in the ProudMe group compared to the control. The investigators also collect mixed-methods data from 24 school implementers at the 6 ProudMe schools and expect to observe appropriate levels of adaptation, fidelity, reach, penetration, and sustainability, with manageable time and financial cost.

NCT ID: NCT06334380 Enrolling by invitation - Breast Cancer Clinical Trials

VR for Surgical Prehabilitation and Rehabilitation

VR-PREP
Start date: April 15, 2024
Phase: N/A
Study type: Interventional

This randomized controlled trial aims to determine feasibility and acceptability of of VR-physical therapy modules for surgical patients undergoing breast or axilla surgery in order to prepare for and recover from surgery.

NCT ID: NCT06334341 Enrolling by invitation - HIV Seropositivity Clinical Trials

A Multilevel, Multiphase Optimization Strategy for PrEP (MOST:PrEP)

MOST:PrEP
Start date: February 21, 2024
Phase: N/A
Study type: Interventional

What is known: There are 1.2 million people in the US who meet the indications for PrEP; yet, disparities exist in uptake. For example, only 9% of Black and 16% of Latino individuals, compared to 65% of White individuals, have been prescribed PrEP. At Henry Ford Health (HFH) system, only 10% of eligible patients have been prescribed PrEP. Primary care is an ideal setting for PrEP to be offered as an HIV prevention method since providers see large numbers of patients who are HIV negative, with some who are at increased risk for HIV, and the primary care setting is often the point of entry to the healthcare system. The multiphase optimization strategy (MOST) framework is a novel, innovative way to identify an efficient intervention. What will be done: In this optimization trial, the investigators will test the effectiveness of intervention components, alone and in combination, on new PrEP prescriptions in primary care at HFH. First, feedback will be generated on context-specific (system and individual level) factors for intervention component delivery via focus groups with providers (n=15) and patients eligible for PrEP (n=30). Then, four intervention components will be tested in an optimization trial, with 16 conditions being implemented at 32 clinics. Finally, feedback will be generated on the factors that affected implementation via semi-structured interviews with providers (n=30) and patients (n=30). Participants will be primary care providers (PCPs) and patients eligible for PrEP in Henry Ford Health System. Clinics will be randomized (yes/no) to receive any combination of provider and patient intervention components. Provider intervention components include computer-based simulation training and/or best practice alerts delivered via the electronic health record (EHR). Patient intervention components include HIV risk assessment and/or PrEP informational video - both delivered via the EHR. Primary outcome is the rate of new PrEP prescriptions at the clinic level. Secondary outcomes will include PrEP maintenance, number of HIV tests ordered by a PCP, and number of PCPs trained. Sub analyses will test which factors moderate (e.g., patient sex, race, age, gender, sexual orientation) or mediate (e.g., perceived HIV risk, provider and patient PrEP knowledge) PrEP uptake, focusing on priority populations and disparities in rates of PrEP prescription. Implications: 1) Understanding which intervention components lead to increased PrEP prescriptions will represent an important advance in HIV prevention efforts. 2) Optimizing a multi-level intervention for providers and patients to increase PrEP prescriptions would lead to a new, efficient, evidence-based option. 3) Determining what factors are related to PrEP uptake will help reduce disparities in PrEP initiation among those most in need. 4) Understanding the context specific factors related to intervention component implementation will help identify best methods for replication/adaptation in other healthcare systems.

NCT ID: NCT06329557 Enrolling by invitation - Clinical trials for Patient Satisfaction

Optimizing the Patient Experience Through Provider Coaching or Communication Intervention

Start date: March 8, 2024
Phase: N/A
Study type: Interventional

Hypothesis: Clinicians who receive patient experience coaching or communication classes have improved patient satisfaction scores and improved clinician satisfaction.